Puff Puff Post

MARCH 10, 2020

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

FEBRUARY 24, 2022

Canada recently amended its Controlled Drugs and Substances Act (CDSA) to allow for psilocybin and MDMA therapy in limited circumstances. Subsection 56(1) of the CDSA will exempt medical providers from enforcement of the CDSA when providing psilocybin and MDMA treatment to patients suffering serious or terminal health conditions.

Therapy 52

Therapy Access Clinical Trials Treatment 52

Veriheal

JUNE 7, 2021

Always consult a physician before attempting alternative therapies. It turns out that this blissful drug, MDMA, has the potential to be used effectively as a treatment for certain conditions- some of which are in urgent need of effective medical assistance. . Conditions That Could Benefit from MDMA Therapy . What is MDMA?

Therapy 92

Therapy Treatment Conditions Clinical Trials 92

Cannabis Law Report

DECEMBER 14, 2021

IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The primary endpoint of our Phase 1 clinical trial was to test and demonstrate safety and tolerability.

Clinical Trials 52

Clinical Trials Safety Data Patients 52

Cannabis Law Report

AUGUST 18, 2022

The firm’s deep expertise in pharmaceutical sciences, FDA regulatory compliance and pharmaceutical product liability litigation and risk management enables it to address complex legal hurdles faced by stakeholders seeking to research, develop, invest in and bring-to-market psychedelic therapies. BUFFALO, N.Y. , Aug. Tweet this.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

The Joint Blog

NOVEMBER 8, 2020

The study concludes by stating that “To our knowledge, this is the first randomized controlled trial to demonstrate the benefit of cannabis oil – a THC-rich whole plant extract – on symptoms and on [the] quality of life of people with fibromyalgia. Interested in reading the study’s full abstract? mg/mL of THC and 0.51

Clinical Trials 49

Clinical Trials Oil Therapy Marijuana 49

Cannabis Law Report

OCTOBER 4, 2021

Advanced Illness , Oregon Psilocybin Advisory Board , Oregon Psilocybin Services Act , Psilocybin , Psilocybin Therapy , Psychedelics , Right To Try. A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions.

Therapy 52

Therapy Patients Law Clinical Trials 52

Veriheal

AUGUST 28, 2023

New therapy exploration suggest potential in using psilocybin for OCD symptoms. And it further reinforces the need to carry out clinical trials to determine the safety and efficiency of using psilocybin to treat OCD. Preliminary findings have suggested that mental health patients could go through psilocybin-assisted therapy.

Treatment 78

Treatment Clinical Trials Therapy Research and Development 78

Cannabis Law Report

MAY 19, 2022

After a psilocybin treatment,(it’s like) you’re still in your car, in traffic, but you have the windows up; the air conditioning is on and it’s quiet. Before January, people could only access psychedelic-assisted psychotherapy through clinical trials or medical exemptions. It’s just you and the music.”

Therapy 52

Therapy Patients Treatment Clinical Trials 52

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 52

Clinical Trials Data Patients THC 52

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. No approved TNF inhibitor has ever been dosed orally.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

CannaMD

AUGUST 26, 2020

A new review published by scientific journal, Pharmacology Biochemistry and Behavior , has found that marijuana cannabinoid, CBD, is a “promising” therapy for treating cocaine dependence. Exploring alternative therapies, researchers turned their attention to marijuana cannabinoid, cannabidiol – more commonly referred to as CBD.

Therapy 98

Therapy CBD Research and Development Treatment 98

Puff Puff Post

MARCH 10, 2020

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. From its anti-inflammatory properties to its ability to alleviate pain, CBD shows promise in addressing various health conditions.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Veriheal

MARCH 20, 2023

Alternative medicine is becoming more widely acknowledged and practiced than ever before, opening the door for therapies like psychedelics to enter the world of mainstream healthcare. Psilocybin therapy is both studied and used by highly legitimate medical establishments. Ned Lamont signed a bill (HB 5506) to fund psychedelic therapy.

Clinical Trials 98

Clinical Trials Therapy Decriminalization Treatment 98

Cannabis Law Report

DECEMBER 5, 2021

Revenue share payments will be based on North America sales of MDMA for use in MDMA-assisted therapy, will terminate after 8 years, and include a reciprocity payment structure that reduces payments once certain financial milestones are met. The safety and efficacy of MDMA-assisted therapy is currently under investigation.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. MEDIA CONTACT .

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

LifeCannMD

FEBRUARY 27, 2024

How Medical Marijuana Is Changing Lives with Crohn’s Disease Medical Marijuana is a great treatment option for battling Crohn’s Disease, a chronic inflammatory bowel condition that affects millions worldwide. Some clinical trials have focused on the anti-inflammatory effects of cannabis in Crohn’s disease.

Marijuana 59

Marijuana Clinical Trials Treatment Therapy 59

Cannabis Law Report

MAY 28, 2022

Natasha Sumner, Kimberly Chew and Karen Luong are attorneys in Husch Blackwell LLP’s virtual office, The Link, and lead the firm’s Psychedelics & Emerging Therapies practice. Husch Blackwell is the first Am Law 100 firm to establish a Psychedelics and Emerging Therapies practice group. How did this come to fruition?

Research and Development 52

Research and Development Therapy Clinical Trials Legalization 52

Veriheal

MAY 25, 2023

Healthcare Ketamine therapy has delivered positive results for patients when used in a structured outpatient setting. In Manhattan alone, 12 clinics have already opened their doors. Many clinics are capitalizing on an opportunity to use ketamine therapy as a treatment for alcoholism, among many other things.

Medicine 98

Medicine Blood Pressure Therapy Clinical Trials 98

Cannabis Law Report

MAY 31, 2022

Two approaches apply to commercial operations—the traditional medical path and the emerging non-medical state-regulated path, while the other two paths are better seen as non-commercial—underground therapy and religious use. 2022 Active FDA Clinical Trials and State-Regulated Systems. Active FDA Regulated Clinical Trials*.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

The Joint Blog

NOVEMBER 4, 2019

Researchers were from the Mayo Clinic. The study found that 58% of physicians agree that “medical cannabis was a legitimate medical therapy.” ” The study concludes: “Providers generally believe that medical cannabis is a legitimate medical therapy. A majority (>?50%)

Therapy 42

Therapy Clinical Trials Conditions Patients 42

CannaMD

MAY 12, 2021

It’s well known that marijuana can be an agent for appetite stimulation, making it a valuable therapy for mitigating the weight loss sometimes associated with conditions such as HIV/AIDS and cancer. The condition can lead to weight gain and obesity. This therapy produced significant weight gain in the subjects.

Marijuana 119

Marijuana Therapy Conditions Food 119

Cannabis Law Report

OCTOBER 19, 2021

Unlike other therapies, MYMD-1 has been shown to selectively block TNF-? In addition, the drug is not immunosuppressive and has not been shown to cause the serious side effects common with traditional therapies that treat inflammation. a driver of chronic inflammation. No approved TNF inhibitor has ever been dosed orally.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Cannabis Law Report

SEPTEMBER 9, 2021

MYMD-1 is also being developed as a potential therapy for COVID-19-related conditions such as post-COVID-19 syndromes. Supera-CBD is being developed to address anxiety, chronic pain, addiction, and seizures, and is on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

Pharmaceutical 97

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 97

SpeedWeed

SEPTEMBER 17, 2021

million to assess the efficacy of Multidisciplinary Association for Psychedelic Studies (MAPS) MDMA-assisted therapy to treat traumatic brain injury (TBI). Wesana is a serious, thoughtful and ethical company engaged in the development of psychedelic-assisted therapy. Lately, MAPS research zeroed in on MDMA-assisted therapy for PTSD.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Cannabis Law Report

AUGUST 25, 2021

Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 111

Clinical Trials Research and Development Therapy Conditions 111

Cannabis Law Report

JANUARY 12, 2022

The sale will accelerate the development of Gb Sciences’ proprietary Parkinson’s disease and COVID-related Cytokine-Release Syndrome therapies. “We can now concentrate all our energies on advancing our plant-inspired, biopharmaceutical research and development programs into human clinical trials.”

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

OCTOBER 5, 2021

Systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of mental health conditions. The Independent Expert Panel was established to undertake a systematic literature review of the roles of MDMA and psilocybin for the treatment of mental health conditions. 30 September 2021.

Treatment 52

Treatment Conditions Medicine Clinical Trials 52

Cannabis Law Report

MAY 10, 2022

Of the 248,000 scripts approved for Australians since inception of national medicinal cannabis scheme in 2016, many related to conditions for which the drug has limited evidence of efficacy, a new University of Sydney study shows. Since the beginning of the program, medicinal cannabis has been prescribed for over 140 conditions.

Medicine 52

Medicine Clinical Trials Sleep Data 52

PrestoDoctor

SEPTEMBER 15, 2023

Obsessive-Compulsive Disorder (OCD) is a debilitating mental health condition that is characterized by intrusive thoughts and compulsive behaviors. While there are a variety of treatments available, many individuals do not find relief with traditional medications or therapies. These obsessions can vary greatly from person to person.

Research and Development 105

Research and Development Therapy Treatment Strains 105

Canna Care Docs

OCTOBER 3, 2023

Natural plant therapy , and cannabis specifically, has been studied for its effectiveness in alleviating and treating many of these physiological and emotional symptoms that come into play with a terminal illness. One study from the Journal of Clinical Oncology examined the efficacy of cannabinoids in appetite stimulation.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Cannabis Law Report

AUGUST 30, 2021

It’s considered a breakthrough therapy,” Dr McTaggart said. “With COVID-19 right now, I think there’s never been a better time to start looking for therapies for mental health.” . “In America the USDA [United States Department of Agriculture] has fast tracked psilocybin treatment.

Clinical Trials 105

Clinical Trials Collective Therapy Treatment 105

Cannabis Law Report

SEPTEMBER 1, 2021

The company recently became the industry’s first firm to list on the NYSE American exchange and their psilocybin clinical trial for depression is making excellent progress. His background is a mix of cognitive psychology, clinical psychology and computer science. Diversified Drug Development.

Research and Development 102

Research and Development Therapy Clinical Trials Pharmaceutical 102

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Key Responsibilities.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Cannabis Law Report

NOVEMBER 9, 2021

As an institution dedicated to diagnosing and treating serious blood diseases and with the ability to pursue investigational medicines from development to manufacture and clinical trial for patients who have exhausted all approved treatment options, having a cost-effective and rapid production chain is integral to ÚHKT’s mission.

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

CannaMD

JUNE 2, 2021

Of those states that had legalized medical marijuana, 14 currently consider Parkinson’s disease a qualifying condition for medical marijuana therapies. Responses came from 49 states, of which 15 had not currently legalized medical marijuana at the time of the study. Florida is among these states.

Patients 105

Patients Clinical Trials Treatment Research and Development 105